phase

Bristol-Myers Squibb Company (NYSE: BMY) today announced positive results from a randomized Phase 2 study evaluating ipilimumab in combination with standard chemotherapy in previously untreated patients with advanced non-small cell lung cancer (NSCLC). The study, known as 041, met the predefined...

Cellceutix Corporation (OTCBB: CTIX), a bio-pharmaceutical company that develops small molecules to treat cancer, autism and inflammatory disease, announced that it has concluded agreements with PharPoint Reasearch for Phase 1 data management and statistical analysis and with Medical Research...

Marshall Edwards, Inc., (NASDAQ: MSHL). An abstract titled "A phase II study of oral phenoxodiol in castrate and non-castrate prostate cancer patients with associated cytokine changes" by Dr Kevin Kelly at the Yale School of Medicine Department of Medical Oncology, is now available at...

In a new Phase III study, BRINAVESSTM (vernakalant) intravenous, an investigational compound being developed in the European Union by Merck (known as MSD outside the USA and Canada) (NYSE: MRK) and Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) to treat atrial fibrillation, showed that...

Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced that data from the Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial evaluating the efficacy and safety of picoplatin as a second-line treatment in small...

Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) (the "Company") announced an agreement with the North Central Cancer Treatment Group (NCCTG) to conduct a phase II study of pixantrone in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but...

April 29, 2010. EnzymeRx, LLC, a clinical-stage biotechnology company, announced top line results from its first clinical trial of pegsitacase (formerly called Uricase PEG 20). Pegsitacase is a pegylated uricase being developed by EnzymeRx for the treatment of refractory gout and for the...

Artisan Pharma, Inc., a private biopharmaceutical company dedicated to bringing best-in-class critical care therapeutics to patients, announced the completion of patient enrollment in its Phase 2b study of ART-123 (Recomodulin® - recombinant human thrombomodulin) in sepsis patients with...

Results from the VeriStrat biomarker analysis of a multicenter Phase III trial were presented at the 2nd European Lung Cancer Conference currently being held in Geneva, Switzerland. Results showed that the VeriStrat test identified patients who were likely to have a survival benefit from...

AFFiRiS AG's clinical Alzheimer's vaccine candidate AD02 has already progressed to phase II clinical testing. It may therefore be possible to confirm the efficacy of the vaccine as early as during 2012. Indeed the start of this efficacy study comes only five months after the completion of the...

ok im 19 male, and i worried that i might be gay at one point, but this has all passed, im back with my ex girlfriend and things have been going great, i love her alot and we get along and sex is great with her, but for a while i preferred gay porn even after i got back with her and realized i...

In an invited presentation today before the annual meeting of the American Academy of Neurology, Knopp Neurosciences Inc. ("Knopp") described further encouraging trends observed in a previously reported Phase 2 study of KNS-760704 (dexpramipexole) in ALS. Knopp reported that post hoc analyses...

I've been in the Army for 13 years, my career is going well. I just found out I probably have clinical DPSD. Anyone else go through this or know someone who has?

Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease (CKD). The data provide...

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) announced the presentation of detailed data, including safety and tolerability data from the open-label extension as well as cardiac safety data from the double-blind phase of the Phase III confirmatory STAR trial evaluating the investigational drug...

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease...

Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease (CKD). The data provide...

AVANIR Pharmaceuticals, Inc. (NASDAQ:AVNR) announced the presentation of detailed data, including safety and tolerability data from the open-label extension as well as cardiac safety data from the double-blind phase of the Phase III confirmatory STAR trial evaluating the investigational drug...

Impax Pharmaceuticals, the brand products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced that it has completed enrollment of its APEX-PD trial. APEX-PD is a multinational Phase III trial of its late-stage drug candidate IPX066 in subjects with early Parkinson's disease...

Affymax, Inc. (Nasdaq: AFFY) and Takeda Global Research & Development Center, Inc., U.S., today announced data from several post hoc analyses of Phase 2 clinical trials that evaluated Hematide/peginesatide in dialysis patients with anemia in chronic kidney disease (CKD). The data provide...